The purpose of this clinical study is to evaluate the safety of OPC-262 (2.5 mg and 5 mg) in patients with type 2 diabetes by long-term administration orally for 52 weeks and to evaluate the efficacy of OPC-262

Inclusion Criteria:

• Patients who completed Study 262-09-001 (namely, patients who visited the hospital at visit Week 24）
• Patients who are capable of giving informed consent prior to participating in this clinical study
• Patients who are able to take contraceptive measures to avoid pregnancy of the patient or the patient's partner for the entire study period and for 4 weeks after the study (end of the post-observation period)

Exclusion Criteria:

• Patients who withdrew from Study 262-09-001
• Patients who experienced serious adverse events that the relationship with the study drug was not denied in Study 262-09-001
• Patients who experienced serious adverse events that the relationship with the study drug are denied in Study 262-09-001 and whose symptoms are still emerged at the time of initiation of this study
• Patients who met the exclusion criteria of Study 262-09-001 during the study period of Study 262-09-001
• Female patients who wish to become pregnant during the study period of Study 262-09-002 or within 4 weeks after the study
• Patients otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the study